Medigene and EpimAb Partner to Advance Off-the-Shelf TCR-TCE Therapies for Cancer

Medigene AG and EpimAb Biotherapeutics, Inc. (EpimAb), announced that the companies have entered a strategic co-development agreement to research and dev...

February 27, 2025 | Thursday | News
Polycythemia Vera A Rare Blood Disorder Affecting Thousands

Polycythemia Vera is a rare disorder marked by a continuous rise in the number of red blood cells in the blood, with an accompanying increase in white bloo...

February 27, 2025 | Thursday | News
HBM Alpha Therapeutics Partners with Global Business Partner to Advance CRH-targeting Therapy for Endocrine Disorders

HBM Alpha Therapeutics (HBMAT), Inc., an innovative biotechnology company incubated by Harbour BioMed, announced a strategic collaboration and license...

February 26, 2025 | Wednesday | News
EMA Approves New 2 mL Pre-Filled Pen Option for TAKHZYRO® to Treat Hereditary Angioedema in Adolescents and Adults

Takeda announced that the EMA has approved an additional 2 mL pre-filled pen option for TAKHZYRO® (lanadelumab) for subcutaneous administration in...

February 25, 2025 | Tuesday | News
Johnson & Johnson Reports Positive Phase 3 ASTRO Study Data for TREMFYA® in Adults with Moderately to Severely Active Ulcerative Colitis

Johnson & Johnson announced data from the Phase 3 ASTRO study of TREMFYA® (guselkumab) subcutaneous (SC) induction therapy in adults with...

February 24, 2025 | Monday | News
European Commission Grants Conditional Marketing Authorization for Gilead’s Seladelpar in Primary Biliary Cholangitis

Gilead Sciences, Inc. announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the treatment of prima...

February 21, 2025 | Friday | News
European Commission Grants Conditional Approval for Merck’s WELIREG® (belzutifan) to Treat VHL Disease-Associated Tumors and Advanced RCC

 Merck known as MSD outside of the United States and Canada, announced that the European Commission (EC) has conditionally approved WELIREG® ...

February 19, 2025 | Wednesday | News
Merck KGaA Ushers in New Leadership Era with Key Executive Appointments

Appointment of three internal senior executives ensures strategic continuity with a new era of leadership Jean-Charles Wirth to become CEO Life Scienc...

February 18, 2025 | Tuesday | News
3Z Pharmaceuticals Unveils Groundbreaking Study Supporting Amlodipine as a Novel Non-Stimulant ADHD Therapy

3Z Pharmaceuticals announced the publication of a transformative study in Neuropsychopharmacology, highlighting compelling scientific evidence that positio...

February 18, 2025 | Tuesday | News
TAHO Pharmaceuticals Announces Positive Preliminary Results for TAH3311, World’s First Oral Resolution Film of Apixaban

TAHO Pharmaceuticals announces positive preliminary results from the pivotal study of TAH3311, the world's first oral resolution film (ODF) of apixaban. Th...

February 18, 2025 | Tuesday | News
Bristol Myers Squibb BMS Reports Five-Year Data: Sotyktu® Maintains Long-Term Efficacy and Safety in Plaque Psoriasis

 Bristol Myers Squibb announced new five-year results from the POETYK PSO long-term extension (LTE) trial of Sotyktu (deucravacitinib) ...

February 17, 2025 | Monday | News
AstraZeneca’s Imfinzi Demonstrates Significant Survival Benefits in Muscle-Invasive Bladder Cancer in NIAGARA Phase III Trial

Results from a post-hoc exploratory subgroup analysis from the NIAGARA Phase III trial showed AstraZeneca’s Imfinzi (durvalumab), administe...

February 17, 2025 | Monday | News
Pfizer's TALZENNA® (talazoparib) + XTANDI® (enzalutamide) Combo Shows Significant Overall Survival Improvement in Metastatic Castration-Resistant Prostate Cancer

Pfizer Inc. announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP)...

February 14, 2025 | Friday | News
Thermo Fisher Scientific Launches Invitrogen™ EVOS™ S1000 Spatial Imaging System

WALTHAM, Mass. Thermo Fisher Scientific Inc., the world leader in serving science, introduced the Invitrogen™ EVOS™ S1000 Spatial Imaging Syste...

February 13, 2025 | Thursday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close